Physician profile
Lawrence King
NPI 1609901487
$20,838.76
in general payments reported to CMS, 2019-2025
37 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $15K · 2021: $1,750 · 2022: $151 · 2023: $353 · 2024: $694 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17,069.10 | 2019-2021 | |
| Argenx US, INC. | $801.54 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $541.03 | 2019-2025 | |
| Lundbeck LLC | $213.38 | 2019-2025 | Vyepti |
| Sk Life Science, INC. | $181.15 | 2022-2025 | |
| Biogen, INC. | $172.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $164.04 | 2019 | |
| Abbvie INC. | $152.22 | 2019-2025 | |
| Amgen INC. | $129.77 | 2019-2025 | Uplizna |
| Genentech USA, INC. | $121.12 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Csl Behring | $118.66 | 2019-2024 | Kcentra |
| Abbott Laboratories | $117.07 | 2023-2025 | Infinity |
| Sunovion Pharmaceuticals INC. | $96.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $93.02 | 2019 | |
| Amneal Pharmaceuticals LLC | $88.85 | 2019-2025 | Crexont |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $70.11 | 2019-2025 | Nuplazid |
| Greenwich Biosciences, INC. | $68.44 | 2019 | |
| Ge Healthcare | $66.67 | 2019 | |
| Ucb, INC. | $64.50 | 2019-2024 | Zilbrysq |
| Avanir Pharmaceuticals, INC. | $60.97 | 2019 | |
| Janssen Biotech, INC. | $55.11 | 2025 | |
| Adamas Pharmaceuticals, INC. | $41.36 | 2019 | |
| Eisai INC. | $41.05 | 2019 | |
| Emd Serono, INC. | $33.71 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.09 | 2019 | |
| Neurocrine Biosciences, INC. | $31.37 | 2025 | |
| Mdd US Operations, LLC | $28.41 | 2019 | |
| Portola Pharmaceuticals, LLC | $26.34 | 2019 | |
| Livanova USA, INC. | $24.27 | 2019 | |
| Averitas Pharma INC. | $24.26 | 2025 | Qutenza |
| Tanabe Pharma America, INC. | $21.18 | 2019 | |
| Akcea Therapeutics, INC. | $19.39 | 2019 | |
| Chiesi USA, INC. | $18.59 | 2024 | Cleviprex |
| Genzyme Corporation | $13.50 | 2019 | |
| Assertio Therapeutics, INC. | $12.69 | 2019 | |
| Lilly USA, LLC | $12.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.